Daniel Paiva Barros de Abreu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Paiva Barros de Abreu has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Andre Macedo Vale
Laboratório de Biologia de Linfócitos, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro
3 shared publications - Renata G. F. Alvim
Cell Culture Engineering Laboratory (COPPE) Universidade Federal do Rio de Janeiro 2030 Horácio Macedo Avenue, Cidade Universitária da Universidade Federal do Rio de Janeiro Rio de Janeiro 21941-598 Brazil ufrj.br
3 shared publications - Alessandra Almeida Filardy
Programa de Pós-Graduação em Ciências (Microbiologia), Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil; Laboratório de Imunologia Celular, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil; Programa de Pós-Graduação em Ciências (Microbiologia), Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Brazil
2 shared publications - Amilcar Tanuri
Federal University of Rio de Janeiro
2 shared publications - Andre Marco Oliveira Gomes
Institute of Medical Biochemistry Leopoldo de Meis and National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, RJ, Brazil
2 shared publications - Andrea Oliveira
Departamento de Química, Universidade Federal do Paraná, Curitiba CEP 81531-980, PR, Brazil
2 shared publications
Latest Publications
- Open Access
Anti-SARS-CoV-2 IgG ELISA: Replacing the Absorbance Plate Reader by a Regular Scanner with Open-Source Software
The COVID-19 global pandemic is still affecting the world, even considering vaccine applications in most countries, especially due to new variant outbreaks and the possibility that they may present immunological escape. Therefore, mass testing is relevant in infection monitoring and restriction policy evaluations, making low-cost and easy-to-use tests essential. Serological tests might also be useful in monitoring immune response after vaccination. The present work proposes a less-expensive ELISA test route, using a scanner instead of a spectrophotometer and using the saturation of the image as a surrogate for the absorbance of each sample. Images from multiple experiments were selected and correlated with their spectrophotometric absorbance. ELISA plate images were digitized by a simple table scanner and, then, preprocessed using Hue, Saturation, Value (HSV) transformation, aiming to determine which correlates best with the obtained absorbance. Saturation correlated better with absorbance, and the experiments presented R consistently above 90% between absorbance and the square of saturation. The new methodology showed similar accuracy, sensitivity, and specificity to the original method, all metrics ranging between 90% and 100% in most cases. An open-source software was also designed to analyze the images, perform the diagnosis, and generate reports.Open AccessAnti-SARS-CoV-2 IgG ELISA: Replacing the Absorbance Plate Reader by a Regular Scanner with Open-Source Software
The COVID-19 global pandemic is still affecting the world, even considering vaccine applications in most countries, especially due to new variant outbreaks and the possibility that they may present immunological escape. Therefore, mass testing is relevant in infection monitoring and restriction policy evaluations, making low-cost and easy-to-use tests essential. Serological tests might also be useful in monitoring immune response after vaccination. The present work proposes a less-expensive ELISA test route, using a scanner instead of a spectrophotometer and using the saturation of the image as a surrogate for the absorbance of each sample. Images from multiple experiments were selected and correlated with their spectrophotometric absorbance. ELISA plate images were digitized by a simple table scanner and, then, preprocessed using Hue, Saturation, Value (HSV) transformation, aiming to determine which correlates best with the obtained absorbance. Saturation correlated better with absorbance, and the experiments presented R consistently above 90% between absorbance and the square of saturation. The new methodology showed similar accuracy, sensitivity, and specificity to the original method, all metrics ranging between 90% and 100% in most cases. An open-source software was also designed to analyze the images, perform the diagnosis, and generate reports. - Open Access
Intradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice
Despite the intramuscular route being the most used vaccination strategy against SARS-CoV-2, the intradermal route has been studied around the globe as a strong candidate for immunization against SARS-CoV-2. Adjuvants have shown to be essential vaccine components that are capable of driving robust immune responses and increasing the vaccination efficacy. In this work, our group aimed to develop a vaccination strategy for SARS-CoV-2 using a trimeric spike protein, by testing the best route with formulations containing the adjuvants AddaS03, CpG, MPL, Alum, or a combination of two of them. Our results showed that formulations that were made with AddaS03 or CpG alone or AddaS03 combined with CpG were able to induce high levels of IgG, IgG1, and IgG2a; high titers of neutralizing antibodies against SARS-CoV-2 original strain; and also induced high hypersensitivity during the challenge with Spike protein and a high level of IFN-γ producing CD4+ T-cells in mice. Altogether, those data indicate that AddaS03, CpG, or both combined may be used as adjuvants in vaccines for COVID-19.
Open AccessIntradermal Immunization of SARS-CoV-2 Original Strain Trimeric Spike Protein Associated to CpG and AddaS03 Adjuvants, but Not MPL, Provide Strong Humoral and Cellular Response in Mice
Despite the intramuscular route being the most used vaccination strategy against SARS-CoV-2, the intradermal route has been studied around the globe as a strong candidate for immunization against SARS-CoV-2. Adjuvants have shown to be essential vaccine components that are capable of driving robust immune responses and increasing the vaccination efficacy. In this work, our group aimed to develop a vaccination strategy for SARS-CoV-2 using a trimeric spike protein, by testing the best route with formulations containing the adjuvants AddaS03, CpG, MPL, Alum, or a combination of two of them. Our results showed that formulations that were made with AddaS03 or CpG alone or AddaS03 combined with CpG were able to induce high levels of IgG, IgG1, and IgG2a; high titers of neutralizing antibodies against SARS-CoV-2 original strain; and also induced high hypersensitivity during the challenge with Spike protein and a high level of IFN-γ producing CD4+ T-cells in mice. Altogether, those data indicate that AddaS03, CpG, or both combined may be used as adjuvants in vaccines for COVID-19.
- Open Access
Immunogenicity of SARS-CoV-2 trimetric spike protein associated to Poly(I:C) plus Alum
The SARS-CoV-2 pandemic has had a social and economic impact worldwide, and vaccination is an efficient strategy for diminishing those damages. New adjuvant formulations are required for the high vaccine demands, especially adjuvant formulations that induce a Th1 phenotype. Herein we assess a vaccination strategy using a combination of Alum and polyinosinic:polycytidylic acid (Poly(I:C)) adjuvants plus the SARS-CoV-2 spike protein in a prefusion trimeric conformation by an intradermal (ID) route. We found high levels of IgG anti-spike antibodies in the serum by enzyme linked immunosorbent assay (ELISA) and high neutralizing titers against SARS-CoV-2 in vitro by neutralization assay, after one or two boosts. By evaluating the production of IgG subtypes, as expected, we found that formulations containing Poly(I:C) induced IgG2a whereas Alum did not. The combination of these two adjuvants induced high levels of both IgG1 and IgG2a. In addition, cellular immune responses of CD4 + and CD8 + T cells producing interferon-gamma were equivalent, demonstrating that the Alum + Poly(I:C) combination supported a Th1 profile. Based on the high neutralizing titers, we evaluated B cells in the germinal centers, which are specific for receptor-binding domain (RBD) and spike, and observed that more positive B cells were induced upon the Alum + Poly(I:C) combination. Moreover, these B cells produced antibodies against both RBD and non-RBD sites. We also studied the impact of this vaccination preparation (spike protein with Alum + Poly(I:C)) in the lungs of mice challenged with inactivated SARS-CoV-2 virus. We found a production of IgG, but not IgA, and a reduction in neutrophil recruitment in the bronchoalveolar lavage fluid (BALF) of mice, suggesting that our immunization scheme reduced lung inflammation. Altogether, our data suggest that Alum and Poly(I:C) together is a possible adjuvant combination for vaccines against SARS-CoV-2 by the intradermal route.
Open AccessImmunogenicity of SARS-CoV-2 trimetric spike protein associated to Poly(I:C) plus Alum
The SARS-CoV-2 pandemic has had a social and economic impact worldwide, and vaccination is an efficient strategy for diminishing those damages. New adjuvant formulations are required for the high vaccine demands, especially adjuvant formulations that induce a Th1 phenotype. Herein we assess a vaccination strategy using a combination of Alum and polyinosinic:polycytidylic acid (Poly(I:C)) adjuvants plus the SARS-CoV-2 spike protein in a prefusion trimeric conformation by an intradermal (ID) route. We found high levels of IgG anti-spike antibodies in the serum by enzyme linked immunosorbent assay (ELISA) and high neutralizing titers against SARS-CoV-2 in vitro by neutralization assay, after one or two boosts. By evaluating the production of IgG subtypes, as expected, we found that formulations containing Poly(I:C) induced IgG2a whereas Alum did not. The combination of these two adjuvants induced high levels of both IgG1 and IgG2a. In addition, cellular immune responses of CD4 + and CD8 + T cells producing interferon-gamma were equivalent, demonstrating that the Alum + Poly(I:C) combination supported a Th1 profile. Based on the high neutralizing titers, we evaluated B cells in the germinal centers, which are specific for receptor-binding domain (RBD) and spike, and observed that more positive B cells were induced upon the Alum + Poly(I:C) combination. Moreover, these B cells produced antibodies against both RBD and non-RBD sites. We also studied the impact of this vaccination preparation (spike protein with Alum + Poly(I:C)) in the lungs of mice challenged with inactivated SARS-CoV-2 virus. We found a production of IgG, but not IgA, and a reduction in neutrophil recruitment in the bronchoalveolar lavage fluid (BALF) of mice, suggesting that our immunization scheme reduced lung inflammation. Altogether, our data suggest that Alum and Poly(I:C) together is a possible adjuvant combination for vaccines against SARS-CoV-2 by the intradermal route.
- Open Access
- 17 May 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (6)
In vitro virulence evaluation of clinical and environmental isolates of dermatophyte fungi
Dermatophytes are keratinophilic fungi and the causative agent of dermatophytosis in animals and people. In the pathogenesis of this disease, enzymes such as DNase, gelatinase, lipase, keratinase, elastase, and collagenase are highlighted. This work aimed to verify the production of these enzymes by clinical and environmental isolates of dermatophytes. Environmental strains were obtained by the Vanbreuseghem technique (1952), using soil samples from different Brazilian locations. The clinical samples were obtained from animal hair and crust sent to the Veterinary Microbiological Diagnostic Service/UFRRJ. The enzymatic evaluation of the dermatophytes was made by spectrophotometer absorbance readings (collagenase, elastase, and keratinase), degradation halo formation in Petri dishes (DNase and lipase) and tube liquefaction (gelatinase). The clinical isolates were Microsporum canis (11), Nannizzia gypsea (7), N. nana (2), Trichophyton mentagrophytes (4) and Trichophyton sp. (6). The environmental isolates were N. gypsea (25), N. nana (1) and Trichophyton sp. (4). There was no statistically significant difference in keratinase, elastase, lipase and gelatinase production between the clinical and environmental isolates groups. There was a statistically significant difference in collagenase and DNase production. It is concluded that both clinical and soil samples are capable of producing enzymes related to dermatophyte infection.
- 17 May 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (6)
Open AccessIn vitro virulence evaluation of clinical and environmental isolates of dermatophyte fungi
Dermatophytes are keratinophilic fungi and the causative agent of dermatophytosis in animals and people. In the pathogenesis of this disease, enzymes such as DNase, gelatinase, lipase, keratinase, elastase, and collagenase are highlighted. This work aimed to verify the production of these enzymes by clinical and environmental isolates of dermatophytes. Environmental strains were obtained by the Vanbreuseghem technique (1952), using soil samples from different Brazilian locations. The clinical samples were obtained from animal hair and crust sent to the Veterinary Microbiological Diagnostic Service/UFRRJ. The enzymatic evaluation of the dermatophytes was made by spectrophotometer absorbance readings (collagenase, elastase, and keratinase), degradation halo formation in Petri dishes (DNase and lipase) and tube liquefaction (gelatinase). The clinical isolates were Microsporum canis (11), Nannizzia gypsea (7), N. nana (2), Trichophyton mentagrophytes (4) and Trichophyton sp. (6). The environmental isolates were N. gypsea (25), N. nana (1) and Trichophyton sp. (4). There was no statistically significant difference in keratinase, elastase, lipase and gelatinase production between the clinical and environmental isolates groups. There was a statistically significant difference in collagenase and DNase production. It is concluded that both clinical and soil samples are capable of producing enzymes related to dermatophyte infection.
- Open Access
Development and large-scale validation of a highly accurate SARS-COV-2 serological test using regular test strips for autonomous and affordable finger-prick sample collection, transportation, and storage
Accurate serological tests are essential tools to allow adequate monitoring and control of COVID-19 spread. Production of a low-cost and high-quality recombinant viral antigen can enable the development of reliable and affordable serological assays, which are urgently needed to facilitate epidemiological surveillance studies in low-income economies. Trimeric SARS-COV-2 spike (S) protein was produced in serum-free, suspension-adapted HEK293 cells. Highly purified S protein was used to develop an ELISA, named S-UFRJ test. It was standardized to work with different types of samples: (i) plasma or serum from venous blood samples; (ii) eluates from dried blood spots (DBS) obtained by collecting blood drops from a finger prick. We developed a cost-effective, scalable technology to produce S protein based on its stable expression in HEK293 cells. Using this recombinant antigen, we presented a workflow for test development in the setting of a pandemic, starting from limited amounts of samples up to reaching final validation with hundreds of samples. Test specificity was determined to be 98.6%, whereas sensitivity was 95% for samples collected 11 or more days after symptoms onset. A ROC analysis allowed optimizing the cut-off and confirming the high accuracy of the test. Endpoint titers were shown to correlate with virus neutralization assessed as PRNT90. There was excellent agreement between plasma and DBS samples, significantly simplifying sample collection, storing, and shipping. An overall cost estimate revealed that the final retail price could be in the range of one US dollar. The S-UFRJ assay developed herein meets the quality requirements of high sensitivity and specificity. The low cost and the use of mailable DBS samples allow for serological surveillance and follow-up of SARS-CoV-2 vaccination of populations regardless of geographical and socio-economic aspects. We hope the detailed guidelines for the development of an affordable and accurate anti-spike SARS-COV-2 ELISA, such as S-UFRJ described here, will stimulate governmental and non-governmental health agencies in other countries to engage in much-needed large-scale studies monitoring the spread and immunity to SARS-COV-2 infection.
Open AccessDevelopment and large-scale validation of a highly accurate SARS-COV-2 serological test using regular test strips for autonomous and affordable finger-prick sample collection, transportation, and storage
Accurate serological tests are essential tools to allow adequate monitoring and control of COVID-19 spread. Production of a low-cost and high-quality recombinant viral antigen can enable the development of reliable and affordable serological assays, which are urgently needed to facilitate epidemiological surveillance studies in low-income economies. Trimeric SARS-COV-2 spike (S) protein was produced in serum-free, suspension-adapted HEK293 cells. Highly purified S protein was used to develop an ELISA, named S-UFRJ test. It was standardized to work with different types of samples: (i) plasma or serum from venous blood samples; (ii) eluates from dried blood spots (DBS) obtained by collecting blood drops from a finger prick. We developed a cost-effective, scalable technology to produce S protein based on its stable expression in HEK293 cells. Using this recombinant antigen, we presented a workflow for test development in the setting of a pandemic, starting from limited amounts of samples up to reaching final validation with hundreds of samples. Test specificity was determined to be 98.6%, whereas sensitivity was 95% for samples collected 11 or more days after symptoms onset. A ROC analysis allowed optimizing the cut-off and confirming the high accuracy of the test. Endpoint titers were shown to correlate with virus neutralization assessed as PRNT90. There was excellent agreement between plasma and DBS samples, significantly simplifying sample collection, storing, and shipping. An overall cost estimate revealed that the final retail price could be in the range of one US dollar. The S-UFRJ assay developed herein meets the quality requirements of high sensitivity and specificity. The low cost and the use of mailable DBS samples allow for serological surveillance and follow-up of SARS-CoV-2 vaccination of populations regardless of geographical and socio-economic aspects. We hope the detailed guidelines for the development of an affordable and accurate anti-spike SARS-COV-2 ELISA, such as S-UFRJ described here, will stimulate governmental and non-governmental health agencies in other countries to engage in much-needed large-scale studies monitoring the spread and immunity to SARS-COV-2 infection.